PepGen Inc.

PEPG

Healthcare|Biotechnology|US

$2.47

+0.15 (+6.47%)

DCF Value

$1.01

Tangible Book / Share

$1.73

Cash / Share

$1.69

About

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Stock Price

-41.3%(1Y)

+3.8%

-13.3%

+40.3%

YTD

-62.1%

-42.0%

-44.9%

-80.8%

Pipeline Summary

5 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 2Terminated: 1Completed: 1Withdrawn: 1

Active Trials (2)

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

NCT06667453Myotonic Dystrophy 1

Phase 2Recruiting

Enrollment: 24 participants

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

NCT07220603Myotonic Dystrophy 1

Phase 2Recruiting

Enrollment: 48 participants

Key Facts

Market Cap$170.8M

Employees56 (-31% YoY)

CEOJames McArthur

IPO DateMay 6, 2022

Beta2.02

52-Week Range$1.31 – $7.8

Avg Volume993,158

ExchangeNASDAQ

Websitepepgen.com

Ownership

Float52.2%

Shares Outstanding69.2M